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Background:  Risk factors for Non-Alcoholic Fatty Liver Disease 
(NAFLD) have reached epidemic proportions and whilst only 
a minority of at-risk individuals develop significant liver dis-
ease warranting specialist referral, ensuring identification of 
this group is a primary care challenge. Non-invasive tests (NIT) 
for liver fibrosis enable community-based doctors to identify 
patients with NAFLD who have advanced fibrosis and would 
benefit from early referral for specialist care and interventions 
to limit the complications of cirrhosis. As part of an evaluation 
of a novel primary care NAFLD pathway in two London bor-
oughs (Camden and Islington, C&I), which uses NIT to stratify 
patients for advanced liver fibrosis, we have constructed an 
analytical model to examine the potential cost implications of 
this strategy on an intention-to-treat basis. Methods: A proba-
bilistic decision analytical model was constructed to explore 
the financial dimensions of two strategies in community based 
management of NAFLD from a healthcare payer perspective: 
1) Standard of care (SOC) comprising physicians’ clinical judg-
ment based on clinical history, examination, blood tests and 
ultrasound 2) SOC plus Non-Invasive Testing for liver fibrosis 
using FIB-4, and the ELF test (to resolve indeterminate FIB-4 
tests) to guide referral. The model was populated from the lit-
erature, national UK data and expert opinion. A five year time 
horizon was applied. Results: The C&I population is 434,958. 
It was assumed that 30% of the NAFLD population consult their 
general practitioner (GP) annually. >F2 fibrosis prevalence in 
NAFLD was set at 5%. Local clinical audit estimated SOC sen-
sitivities and specificities of 0.35 and 0.70. The model esti-
mated 24% needed ELF test. Utilizing NIT reduced referrals of 
≤F2 disease by over 80% and resulted in over 50% increase 
in the detection of cirrhosis. There was a significant reduc-
tion in liver transplantation rates by approximately 15%. The 
overall expenditure was reduced by a fifth, primarily through 
reductions in referrals for low risk cases, costs related to HCC 
management and emergency inpatient admissions. Discussion: 
The use of NIT led to a reduction in inappropriate referrals and 
improvement in the early detection of cirrhosis and its compli-
cations. These changes are likely to result in significant health 
gains and economic cost savings. With NAFLD prevalence 
likely to increase, policy needs to address these challenges. 
Modeling suggests that the Camden and Islington NAFLD path-
way employing FIB-4 and ELF to guide GPs’ risk stratification 
of patients will achieve these goals. A full clinical effectiveness 
and cost consequence analysis is underway.
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